LEUKOPENIA AS THE ONLY SYMPTOM OF COVID-19 IN PATIENTS WITH SCHIZOPHRENIA ON CLOZAPINETHERAPY
Abstract
Patients suffering from Covid-19 often have leukopenia, most often lymphopenia, as an accompanying laboratory manifestation of the clinical syndrome, but there are indications that at the beginning of the disease they also have mild neutropenia. Clozapine can have hematological side effects in terms of leukopenia - most often neutropenia.
The paper presents a patient with schizophrenia who is on long-term clozapine therapy. At the time when leukopenia was detected in the blood count, he was mentally stable and physically asymptomatic. He had a reduced number of leukocytes as the only symptom of infection with the new coronavirus SARS CoV 2, which we confirmed by PCR. In this paper, we present the clinical picture of Covid-19 in connection with the possible overlapping etiology of leukopenia, which can also appear as a separate symptom of infection with the SARS CoV 2 coronavirus and be a hematological side effect of clozapine treatment.
References
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet. 2020;395:497–506.
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395: 507–513.
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054–1062.
Guan WJ, Ni ZY, Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382: 1708–1720.
Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng, Y, et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis. International journal of infectious diseases. 2019; 96:131-135.
Wang D, Hu B, Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323: 1061–1069.
Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed. Cambridge: Cambridge University Press; 2013.
Li XH, Zhong XM, Lu L. The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies. Psychol Med. 2020; 50: 583–594.
Stahl SM. Stahl's Essential Psychopharmacology: The Prescriber's Guide 6th ed. New York: Cambridge University Press; 2017.
Geldenhuys C, Zunza M, Tiffi N, Koen L, Decloedt EH. Clozapine-Associated Leukopenia and Agranulocytosis in Western Cape, South Africa: A 3-Year Retrospective Cohort Study. Journal of Clinical Psychopharmacology. 2021;41(3):250-254.
Mijovic A, MacCabe JH. Clozapine-induced agranulocytosis. Annals of hematology. 2020;99(11):2477-2482.
Myles N, Myles H, Xia S. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand. 2018;138:101–109.
Munshi, HG, Montgomery, RB. Severe neutropenia: a diagnostic approach. West J Med. 2000; 172:248–252.
Zhang, X, Tan, Y, Ling, Y, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature. 2020;583(7816):437-440.
Lowery SA, Sariol A, Perlman S. (2021). Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19. Cell Host Microbe. 2021;29(7):1052-1062.
Elbe D, Black TR, McGrane IR, Procyshyn RM. Clinical Handbook of Psychotropic Drugs for Children and Adolescents, 4th ed. Boston: Hogrefe Publishing Corporation; 2019. p.160.
Rajagopal S . Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgrad Med J. 2005;81:545–546.
Gee S, Taylor D. The effect of COVID-19 on absolute neutrophil counts in patients taking clozapine. Ther Adv Psychopharmacol [Internet]. 2020 Jul 16 [cited 2022 Mar 16];16:10:2045125320940935. Available from: Doi: 10.1177/2045125320940935
Rajić Z, Dunjić B, Milivojević G, Cvetić T, Simončević M, Mirosavljević S, et al. Uspešan oporavak pacijentkinje sa razvojem granulocitopenije tokom terapije klozapinom. Engrami. 2008;30(1):67-72.
De Leon J, Ruan CJ, Schoretsanitis G, De las Cuevas C. A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology. Psychother Psychosom. 2020;89(4):200-214.